Onconetix (NASDAQ:ONCO) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen cut shares of Onconetix (NASDAQ:ONCO) from a hold rating to a sell rating in a report issued on Sunday morning.

Onconetix Stock Performance

Shares of Onconetix stock opened at $4.19 on Friday. The stock’s 50-day simple moving average is $5.98 and its 200-day simple moving average is $23.20. Onconetix has a 52 week low of $3.82 and a 52 week high of $1,190.00.

Onconetix (NASDAQ:ONCO) last issued its earnings results on Thursday, June 12th. The company reported $21.25 earnings per share (EPS) for the quarter. Onconetix had a negative return on equity of 514.04% and a negative net margin of 2,913.71%. The company had revenue of $0.10 million for the quarter.

Hedge Funds Weigh In On Onconetix

A hedge fund recently bought a new stake in Onconetix stock. Millennium Management LLC purchased a new position in Onconetix, Inc. (NASDAQ:ONCO) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 39,477 shares of the company’s stock, valued at approximately $25,000. Millennium Management LLC owned approximately 0.48% of Onconetix as of its most recent SEC filing. 23.89% of the stock is currently owned by hedge funds and other institutional investors.

Onconetix Company Profile

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.